These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36098270)

  • 21. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
    Gao TT; Shan JH; Yang YX; Zhang ZW; Liu SL; Xi M; Liu MZ; Zhao L
    BMC Cancer; 2022 Sep; 22(1):992. PubMed ID: 36115960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How we treat esophageal squamous cell carcinoma.
    Puhr HC; Prager GW; Ilhan-Mutlu A
    ESMO Open; 2023 Feb; 8(1):100789. PubMed ID: 36791637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
    Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
    Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma.
    Guo JC; Lin CC; Hsu CL; Huang TC; Kuo HY; Lin CY; Lien MY; Cheng AL; Hsu CH
    Esophagus; 2022 Oct; 19(4):693-701. PubMed ID: 35816242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of sequential lines of palliative chemotherapy in patients with recurrent/metastatic esophageal squamous cell carcinoma: A retrospective analysis of 107 patients at a single center.
    Kim EJ; Kim JH; Song HJ; Park SR; Kim YH; Kim HR; Kim SB
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e53-e62. PubMed ID: 31657877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
    Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
    Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The Development of Combinatorial Cancer Immunotherapy with Anti-PD-1 Therapy and Radiotherapy for Patients with Esophageal Squamous Cell Carcinoma].
    Mimura K; Kono K
    Gan To Kagaku Ryoho; 2022 Sep; 49(9):914-916. PubMed ID: 36156004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A global perspective in second-line treatment patterns for patients with advanced esophageal squamous cell carcinoma.
    Jaffe DH; Gricar J; DeCongelio M; Mackie DS
    Thorac Cancer; 2022 May; 13(9):1240-1257. PubMed ID: 35355433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions.
    Jiang M; Hu Y; Lin G; Chen C; Li H
    Front Immunol; 2023; 14():1177085. PubMed ID: 37325652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma.
    Ohsawa M; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Kitasaki N; Okada M
    Front Oncol; 2023; 13():1126536. PubMed ID: 37139161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
    Waterhouse D; Lam J; Betts KA; Yin L; Gao S; Yuan Y; Hartman J; Rao S; Lubinga S; Stenehjem D
    Lung Cancer; 2021 Jun; 156():41-49. PubMed ID: 33894493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging data on nivolumab for esophageal squamous cell carcinoma.
    Hirose T; Yamamoto S; Kato K
    Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
    Liu Y; Ge Q; Xu S; Li K; Liu Y
    Front Oncol; 2022; 12():942678. PubMed ID: 36059654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
    Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab for the treatment of esophageal cancer.
    Yamamoto S; Kato K
    Expert Opin Biol Ther; 2020 Oct; 20(10):1143-1150. PubMed ID: 32620063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
    Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.